Roche CEO Is Confident on Growth Beyond 2019

The transcript discusses the impact of biosimilars on the business, highlighting the introduction of biosimilar versions of Avastin and Herceptin in the US. It covers the company's strategy to offset this impact through new growth products like Oakleaves and Hemlibra. The discussion also touches on US legislation affecting drug pricing and the Chinese market's growth potential. The acquisition of Spark Therapeutics is addressed, emphasizing confidence in closing the deal and the benefits of gene therapy. Finally, the importance of innovation in the pharmaceutical industry is underscored.

What markets are currently most important for growth as mentioned in the text?

How does the speaker view the potential impact of the Spark Therapeutics acquisition?

What is the significance of innovation in the pharmaceutical industry according to the speaker?